Glutaminase Inhibition to Treat Cancer, Cardiac Ischemia and Stoke

Abstract (Set) A common occurrence in cancer is altered glucose metabolism where cells take up glucose avidly and convert it primarily to lactate, despite available oxygen. These cells also depend on continued mitochondrial function for metabolism, specifically glutaminolysis that catabolizes glutamine to generate ATP and lactate. Glutamine is highly transported into proliferating cells, is a major energy source and substrate for anabolic processes in cancer cells, and is thought be cardioprotective in patients with cardiac ischemia, but the regulation of glutamine metabolism is not well understood. JHU scientists have discovered a method to inhibit glutamine metabolism using synthetic oligonucleotides offering therapeutic opportunities for cancer, cardiac ischemia and stroke. Description (Set) Key Features ? Novel discovery of specific molecules that target glutaminase. ? Synthetic oligonucleotides target glutaminase and inhibit glutamine catabolism for treatment of cancer. ? Anti-sense synthetic oligonucleotides result in increased glutaminase offering protection against ischemic cell death seen in cardiac ischemia or stroke. Proposed Use (Set) General commercial potential includes anti-cancer agents, and treatments for cardiac ischemia and stroke.

Inventor(s): Inventor (Set) Dang, Chi V. ,Gao, Ping

Type of Offer: Licensing



« More Medical Patents

---